



(11) **EP 3 118 211 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 71

(48) Corrigendum issued on:
06.09.2017 Bulletin 2017/36

(43) Date of publication:
18.01.2017 Bulletin 2017/03

(21) Application number: **15761359.7**

(22) Date of filing: **27.02.2015**

(51) Int Cl.:
C07K 5/06 (2006.01) **C07K 5/037** (2006.01)
A61K 38/05 (2006.01) **A61P 31/12** (2006.01)
A61P 31/14 (2006.01) **A61P 31/20** (2006.01)
A61P 31/04 (2006.01) **A61P 27/02** (2006.01)
A61P 11/00 (2006.01) **A61P 11/06** (2006.01)
A61P 1/04 (2006.01) **A61P 1/16** (2006.01)

(86) International application number:
PCT/RU2015/000121

(87) International publication number:
WO 2015/137846 (17.09.2015 Gazette 2015/37)

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: **12.03.2014 RU 2014109441**

(71) Applicant: **Obschestvo S Ogranichennoi**
Otvetstvennosti
"Pharmenterprises"
Moscow 117571 (RU)

(72) Inventors:
• **NEBOLSIN, Vladimir Evgenievich**
Istrinsky r-n
Moskovskaya obl. 143581 (RU)
• **KROMOVA, Tatyana Alexandrovna**
Kaluga 248010 (RU)

(74) Representative: **Hoffmann Eitle**
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München (DE)

(54) **AMIDE COMPOUNDS AND METHODS FOR THE PRODUCTION AND USE THEREOF**

(57) The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treat-

ment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirivirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.

EP 3 118 211 A8